Telo Genomics Corp. (TELO) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 5 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.49

Return on Equity

-999,999.00%

Price to Book

-5.02

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-28.57%

6 Months

-33.33%

1 Year

-54.55%

2 Years

-72.22%

3 Years

-86.11%

4 Years

-84.62%

5 Years

-77.27%

Telo Genomics Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.11

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.78

EV to EBIT

-1.93

EV to EBITDA

-1.96

EV to Capital Employed

-5.24

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-408.91%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -33.33% vs 14.29% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.80",
          "val2": "-0.60",
          "chgp": "-33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.80",
          "val2": "-0.60",
          "chgp": "-33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 0.00% vs 0.00% in Jun 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is 3.57% vs -33.33% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.70",
          "val2": "-2.80",
          "chgp": "3.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.70",
          "val2": "-2.80",
          "chgp": "3.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.80

-0.60

-33.33%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-0.80

-0.60

-33.33%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -33.33% vs 14.29% in Mar 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'24

Jun'24

Jun'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.70

-2.80

3.57%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.70

-2.80

3.57%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2024 is 0.00% vs 0.00% in Jun 2023

Consolidated Net Profit

YoY Growth in year ended Jun 2024 is 3.57% vs -33.33% in Jun 2023

All Annual Results

Company CV

About Telo Genomics Corp.

Telo Genomics Corp.

Pharmaceuticals & Biotechnology

Telo Genomics Corp, formerly 3D Signatures Inc, is a Canada-based personalized medicine company with a software platform based on the three-dimensional (3D) analysis of telomere organization. Its TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and manage an individual’s disease based on their TeloViewTM score. Its software-based technology and prognostic methodology target various diseases that demonstrate genomic instability, including cancer and neurological disorders. It is engaged in developing over five diagnostic and prognostic products for cancers and neurological disorders, including TELO-HL, Telo-MM, Telo-PC, Telo-LC and Telo-AD. Its Telo-PC enables clinicians to identify patient stability during diagnosis, optimize treatment plans and manage to monitor with a non-invasive blood test. Its technology analyzes a specific part of an individual’s deoxyribonucleic acid to determine how a disease progress.

Company Coordinates

Company Details

Mars Centre, 101 College St Suite 200 , TORONTO ON : M5G 1L7

Tel: 1 416 6738487

http://www.3dsignatures.com/

Registrar Details